- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Palatin finalizes partnership with Mallinckrodt
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatin’s radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement,
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatins radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement, Mallinckrodt paid Palatin a licensing fee of $500,000 and acquired 700,000 restricted unregistered shares of Palatin preferred stock for an additional $13 million. An extra $10 million in milestone payments will be paid to Palatin upon Food and Drug Administration approval of the first indication for LeuTech, and the attainment of certain sales goals following the commercial introduction of this product. St. Louis-based Mallinckrodt will also reimburse Palatin for 50% of all ongoing LeuTech development costs, while Palatin, which is based in Princeton, NJ, will manufacture LeuTech and receive a transfer price on each product unit and a royalty on net LeuTech sales.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
